Fundz Deep Dive
Everything you need to win Bridge Biotherapeutics — in one platform.
Who to reach, what to say, and why now on Bridge Biotherapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Bridge Biotherapeutics — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Bridge Biotherapeutics and HitGen Initiate Research Collaboration for Cancer Therapeutics
Aug 22, 2024•almost 2 years ago
Contract Type
partnership
ChengduBiotechnologyBiopharmaDescription
Bridge Biotherapeutics and HitGen have entered into a joint research agreement to advance novel cancer therapeutics program. The collaboration aims to develop promising drug candidates for various types of cancer, building on the successful initial hit finding and identification work from HitGen's DNA-encoded library (DEL).
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months